在被诊断为前列腺癌的男性中,偏好诱导和治疗决策:的随机对照试验结果
Michael A Diefenbach1, Allison Marziliano1, Erin K Tagai2
1Institute of Health System Science, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, United States.
Journal of medical Internet research
|October 20, 2023
概括
一个简短的基于网络的工具Healium有效地引起患者对前列腺癌治疗决策的偏好,在减少决策冲突和提高满意度方面表现出与综合性辅助工具相似的有效性.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 医疗保健服务研究 医疗服务研究
- 决策科学 决策科学 决策科学
背景情况:
- 共享决策对于前列腺癌治疗选择至关重要.
- 现有的决策辅助工具往往忽视了患者偏好的诱导.
- 是一种新的,简短的,基于网络的工具,专为低健康素养人口设计,以引起治疗偏好.
研究的目的:
- 评估Healium对Healing Choices的有效性,这是一个全面的决策辅助工具,用于改善前列腺癌患者的决策结果和情感生活质量.
- 评估Healium在局部前列腺癌治疗决策的偏好诱导方面的有效性.
主要方法:
- 一项随机对照试验在等待治疗决定的局部前列腺癌患者中进行.
- 参与者被随机分配到Healium干预或Healing Choices决策辅助器.
- 决策冲突,满意度,决策准备,焦虑和抑郁被评估在基线,6周和3个月.
主要成果:
- 和治疗选择都显著减少了决策冲突,并增加了决策满意度.
- 在两组中都观察到抑郁症的显著下降.
- 对于任何干预措施,都没有注意到焦虑/紧张的显著变化.
结论:
- 在减少前列腺癌患者的决策冲突方面,Healium与全面的Healing Choices工具一样有效.
- 的简洁性使得它适合整合到临床工作流程和电子医疗记录中.
- 该工具成功地引出了患者的偏好,支持前列腺癌护理的共享决策.
相关概念视频
Blinding
2.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.5K
Cancer Survival Analysis
357
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
357
Hazard Ratio
137
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
137


